Bio-Sourcing and Tiny Cargo Partner to Develop First Oral Monoclonal Antibody Platform Using Goat Milk Exosomes
核心洞察
Bio-Sourcing SA (搜索) and The Tiny Cargo Company (搜索) announced a strategic collaboration to develop oral monoclonal antibody therapies using goat milk-derived exosomes, potentially eliminating the need for injections.
The partnership combines Bio-Sourcing's platform for producing high-yield, low-cost monoclonal antibodies (搜索) in goat milk with Tiny Cargo's cGMP-ready industrial platform for purifying and loading milk-derived exosomes.
Currently, no oral monoclonal antibodies (搜索) are approved by FDA or EMA, making this alliance a potential breakthrough in pharmaceutical innovation for the hundreds of millions of patients reliant on injectable mAbs.
Bio-Sourcing SA (搜索) and The Tiny Cargo Company (搜索) announced a strategic EU-US collaboration on March 18, 2026, to co-develop oral therapies based on monoclonal antibodies (搜索) (mAbs) using goat milk-derived extracellular vesicles, including exosomes. This partnership aims to create the first-of-its-kind oral delivery platform for biologics, potentially transforming treatment accessibility for millions of patients worldwide.
Revolutionary Approach to Oral Biologics
The collaboration unites two proprietary technological platforms to address a longstanding challenge in pharmaceutical development. Bio-Sourcing's platform expresses monoclonal antibodies (搜索) in the milk of a particular breed of goats at industrial scale, enabling purification of the antibody while simultaneously producing milk EVs. The platform offers significant cost and scalability advantages over conventional bioreactors, opening pathways to broader access and sustainable manufacturing.
Tiny Cargo has developed the world's first cGMP-ready industrial manufacturing capability for highly purified milk-derived exosomes, supported by proprietary purification and loading processes designed to isolate exosomes from milk and incorporate complex therapeutic payloads. The platform is designed for pharmaceutical-grade production and supports applications across therapeutics, nutraceuticals and advanced skincare.
"With Tiny Cargo, we're pairing two outstanding product platforms — Bio-Sourcing's high-yield, sustainable goat-milk manufacturing of monoclonal antibodies (搜索) and milk EVs with Tiny Cargo's industrial-scale milk exosome isolation and loading — to unlock true oral delivery for biologics," said Bertrand Mérot, founder and CEO of Bio-Sourcing SA (搜索).
Natural Delivery System Advantages
Milk-derived exosomes are naturally designed to survive the gastrointestinal tract and deliver antibodies to the bloodstream, making them an especially promising carrier for oral drug delivery. This evolutionary advantage addresses the historical vulnerability of monoclonal antibodies (搜索) to gastrointestinal breakdown, which has traditionally required delivery via injection or infusion.
"Milk-derived exosomes are among the most resilient delivery systems in nature," said Alan Gourdie, CEO of The Tiny Cargo Company (搜索). "The ability to source both the antibody and the delivery vehicle from the same biological starting point is a rare and powerful advantage. For the hundreds of millions of patients currently reliant on injectable mAbs, transitioning to an oral format would fundamentally transform how biologics are prescribed, distributed and accessed globally."
Clinical and Commercial Potential
Oral delivery of mAbs promises clear benefits for patients and health systems, including elimination of needles, fewer hospital visits, and a path to stable, shelf-ready formulations. The collaboration will focus on associating Bio-Sourcing-derived mAbs with goat-milk EVs and evaluating therapeutic applications via the oral route, with the shared objective of building a new class of patient-friendly, stable biologics.
Currently, there are no FDA or EMA-approved oral mAbs, underscoring the innovation potential of this alliance and positioning the partnership as a leader in pharmaceutical innovation.
Established Track Record
Bio-Sourcing has demonstrated its expertise through twice receiving competitive Eurostars funding from the European Union. In 2024, the company led a consortium to develop an oral adalimumab, and in 2026, alongside an EU partner, it was granted funding to advance an oral anti-HER2 (搜索) trastuzumab, reinforcing its position at the forefront of oral mAb delivery.
The strategic alliance also provides mutual geographic benefits, broadening Bio-Sourcing's access to American collaborations while offering Tiny Cargo a strong foothold in Europe. Both companies will attend the Bio Europe Spring Conference and LSX in Lisbon, Portugal, on March 25-26, 2026.